About Mineralys Therapeutics, Inc.
https://mineralystx.comMineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension.
CEO
Jon Congleton
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 126
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Stifel
Buy
HC Wainwright & Co.
Buy
Goldman Sachs
Buy
B of A Securities
Buy
Guggenheim
Buy
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
CATALYS PACIFIC, LLC
Shares:8.9M
Value:$297.52M
RA CAPITAL MANAGEMENT, L.P.
Shares:7.32M
Value:$244.72M
SAMSARA BIOCAPITAL, LLC
Shares:6.26M
Value:$209.28M
Summary
Showing Top 3 of 202
About Mineralys Therapeutics, Inc.
https://mineralystx.comMineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $41.12M ▼ | $-36.93M ▲ | 0% | $-0.52 ▲ | $-36.92M ▲ |
| Q2-2025 | $0 | $46.75M ▲ | $-43.27M ▼ | 0% | $-0.66 ▲ | $-46.73M ▼ |
| Q1-2025 | $0 | $44.45M ▼ | $-42.21M ▲ | 0% | $-0.79 ▲ | $-44.43M ▲ |
| Q4-2024 | $0 | $51.77M ▼ | $-48.95M ▲ | 0% | $-0.98 ▲ | $-51.75M ▲ |
| Q3-2024 | $0 | $60.11M | $-56.34M | 0% | $-1.13 | $-60.09M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $217.6M ▼ | $599.95M ▲ | $23.52M ▲ | $576.43M ▲ |
| Q2-2025 | $324.92M ▼ | $335.72M ▼ | $22.17M ▲ | $313.55M ▼ |
| Q1-2025 | $343.03M ▲ | $354.94M ▲ | $13.39M ▼ | $341.56M ▲ |
| Q4-2024 | $198.19M ▼ | $205.9M ▼ | $14.65M ▼ | $191.26M ▼ |
| Q3-2024 | $263.6M | $268.25M | $31.32M | $236.93M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-36.93M ▲ | $-28.87M ▲ | $-150.51M ▼ | $295.19M ▲ | $115.81M ▲ | $-28.87M ▲ |
| Q2-2025 | $-43.27M ▼ | $-30.17M ▲ | $-42.88M ▲ | $9.83M ▼ | $-63.22M ▼ | $-30.17M ▲ |
| Q1-2025 | $-42.21M ▲ | $-45.49M ▲ | $-92.88M ▼ | $189.28M ▲ | $50.92M ▲ | $-45.49M ▲ |
| Q4-2024 | $-48.95M ▲ | $-66.84M ▼ | $83.57M ▲ | $90K ▲ | $16.82M ▼ | $-66.84M ▼ |
| Q3-2024 | $-56.34M | $-50.19M | $79.61M | $-1K | $29.42M | $-50.22M |
CEO
Jon Congleton
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 126
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Stifel
Buy
HC Wainwright & Co.
Buy
Goldman Sachs
Buy
B of A Securities
Buy
Guggenheim
Buy
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
CATALYS PACIFIC, LLC
Shares:8.9M
Value:$297.52M
RA CAPITAL MANAGEMENT, L.P.
Shares:7.32M
Value:$244.72M
SAMSARA BIOCAPITAL, LLC
Shares:6.26M
Value:$209.28M
Summary
Showing Top 3 of 202